CREATION OF A FAVORABLE INVESTMENT ENVIRONMENT IN THE PHARMACEUTICAL INDUSTRY
Abstract
The drug business assumes an essential part in present day culture by creating life-saving and life-upgrading meds. In any case, this industry requires colossal capital speculations to finance innovative work of new medications. As indicated by insights, it takes more than $2.6 billion on normal to foster another medication and get administrative endorsement. Given these significant expenses, legislatures and industry partners should attempt to lay out good circumstances that empower proceeded with interests in drug exploration and development. This article dissects a few key factors that can assist with establishing a positive speculation climate for this significant industry.
Keywords
Developed fields, developments, research, industry, donations, costs.
References
- Erick & Co., Inc. 1989 Annual Report. Rahway: Merck & Co., Inc., 1990.
- Veverka MJ. Pharmaceuticals. New York, Booz Allen & Hamilton, 1989.
- Patent Departments, Merck & Co., Inc., and Hoffman-La Roche. Unpublished study of 77 human and animal health products approved from September 1984 through 1989.
- Worldwide pharma R&D trends. Scrip 1989; 1471: 25.
- Narin F, Davidson FJ. The growth of Japanese science and technology. Science 1989; 245: 600-606.
- Pharmaceutical Manufacturers Association. Industry Perspective: Drug Prices. Washington, D.C.: Pharmaceutical Manufacturers Association, 1989.
- Gannes S. The good news about U.S. R&D. Fortune 1988; 117: 48-56.
- Science Foundation, 1988. National Science Foundation. NSF Fact Book. Washington, D.C.: National Science Foundation;